

NCT ID	NCT04185883
Title	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Phase	Phase 1
Date Added	2019-12-04
Location	Arizona, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Maryland, United States Michigan, United States Missouri, United States New York, United States North Carolina, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Australia Austria Belgium Canada Germany Italy Japan Netherlands South Korea Spain Taiwan United Kingdom
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	afatinib, AMG 404, Atezolizumab, carboplatin, pemetrexed, docetaxel, everolimus, FOLFIRI, FOLFOX, MVASI® (bevacizumab-awwb), palbociclib, panitumumab, Pembrolizumab, RMC-4630, Sotorasib, TNO155, Trametinib
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06850103
Title	SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer with Oligometastases
Phase	Phase 2
Date Added	2025-02-27
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT06835179

Title	SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
Phase	Phase 2
Date Added	2025-02-19
Location	
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT06794086
Title	SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
Phase	Phase 3
Date Added	2025-01-27
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT03313778
Title	Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors
Phase	Phase 1
Date Added	2017-10-18
Location	District of Columbia, United States Florida, United States Massachusetts, United States New York, United States Ohio, United States Pennsylvania, United States Australia Japan United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	mRNA-4157, Pembrolizumab, Keytruda
Tags	MSS/ MMRp
NCT ID	NCT02617277
Title	Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
Phase	Phase 1
Date Added	2015-11-30
Location	Colorado, United States Florida, United States Tennessee, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting

Drugs	AZD1775, MEDI4736
Tags	MSS/ MMRp
NCT ID	NCT05243862
Title	Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
Phase	Phase 2
Date Added	2022-02-17
Location	Arizona, United States Florida, United States Minnesota, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab, PolyPEPI1018, Tecentriq
Tags	MSS/ MMRp
NCT ID	NCT06065371
Title	Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Phase	Phase 1
Date Added	2023-10-03
Location	Michigan, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	capecitabine, Sacituzumab govitecan
Tags	MSS/ MMRp
NCT ID	NCT03365882
Title	S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
Phase	Phase 2
Date Added	2017-12-07

Location	Alaska, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Puerto Rico
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta
Tags	MSS/ MMRp

NCT ID	NCT05733611
Title	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Phase	Phase 2
Date Added	2023-02-17
Location	
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSS/ MMRp